FRANKFURT, Nov 10 (Reuters) - BioNTech on Tuesday signalled that order size would impact the per-dose price for its potential COVID-19 vaccine in the developed world.
“The price for the U.S. for the first 100 million doses was $19.50 per dose,” said BioNTech’s Chief Strategy Officer Ryan Richardson in an analyst call after the release of third quarter results on Tuesday.
He was referring to a July deal struck by partner Pfizer with the U.S. government for the supply of the vaccine.
“You can think about that as a benchmark for how we would price the vaccine to the developed world for similar volumes,” he added.
Reporting by Ludwig Burger Editing by Edward Taylor
Our Standards: The Thomson Reuters Trust Principles.